The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
800
Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Blood pressure reduction with reference to genetic polymorphisms.
Time frame: Over 1 Year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.